S&P 500   4,586.18 (-1.48%)
DOW   34,600.29 (-1.52%)
QQQ   393.50 (-1.55%)
AAPL   164.02 (+2.36%)
MSFT   330.98 (-1.68%)
FB   326.94 (-3.28%)
GOOGL   2,848.77 (-2.12%)
AMZN   3,505.70 (-1.57%)
TSLA   1,129.81 (-0.63%)
NVDA   321.52 (-3.67%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.70 (-1.67%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,586.18 (-1.48%)
DOW   34,600.29 (-1.52%)
QQQ   393.50 (-1.55%)
AAPL   164.02 (+2.36%)
MSFT   330.98 (-1.68%)
FB   326.94 (-3.28%)
GOOGL   2,848.77 (-2.12%)
AMZN   3,505.70 (-1.57%)
TSLA   1,129.81 (-0.63%)
NVDA   321.52 (-3.67%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.70 (-1.67%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,586.18 (-1.48%)
DOW   34,600.29 (-1.52%)
QQQ   393.50 (-1.55%)
AAPL   164.02 (+2.36%)
MSFT   330.98 (-1.68%)
FB   326.94 (-3.28%)
GOOGL   2,848.77 (-2.12%)
AMZN   3,505.70 (-1.57%)
TSLA   1,129.81 (-0.63%)
NVDA   321.52 (-3.67%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.70 (-1.67%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,586.18 (-1.48%)
DOW   34,600.29 (-1.52%)
QQQ   393.50 (-1.55%)
AAPL   164.02 (+2.36%)
MSFT   330.98 (-1.68%)
FB   326.94 (-3.28%)
GOOGL   2,848.77 (-2.12%)
AMZN   3,505.70 (-1.57%)
TSLA   1,129.81 (-0.63%)
NVDA   321.52 (-3.67%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.70 (-1.67%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
NYSE:GSK

GlaxoSmithKline Price Target, Predictions & Analyst Ratings

$41.09
-0.27 (-0.65%)
(As of 11/30/2021 01:26 PM ET)
Add
Compare
Today's Range
$40.94
$41.66
50-Day Range
$38.05
$43.53
52-Week Range
$33.53
$43.61
Volume
210,756 shs
Average Volume
4.08 million shs
Market Capitalization
$110.64 billion
P/E Ratio
17.41
Dividend Yield
5.03%
Beta
0.72

GlaxoSmithKline (NYSE:GSK) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 10 Analyst Ratings

Analyst Price Target Consensus

$0.00

High PT$0.00
Average PT$0.00
Low PT$0.00
TypeCurrent
11/30/20 to 11/30/21
1 Month Ago
10/31/20 to 10/31/21
3 Months Ago
9/1/20 to 9/1/21
1 Year Ago
12/1/19 to 11/30/20
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
6 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Price Target UpsideN/AN/AN/AN/A
Get GlaxoSmithKline Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GlaxoSmithKline (NYSE:GSK) vs. Its Competitors

TypeGlaxoSmithKlineMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.72
2.56
Consensus RatingHoldBuyBuy
Price Target Upside186.86% Upside13.66% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
771
57.11%
Underperform Votes
579
42.89%
Avg. Outperform Votes
176
67.43%
Avg. Underperform Votes
85
32.57%
Avg. Outperform Votes
834
69.44%
Avg. Underperform Votes
367
30.56%

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/24/2021Berenberg Bank
Reiterated RatingBuy
11/8/2021UBS Group
Reiterated RatingNeutral
11/5/2021Barclays
UpgradeUnderweight ➝ Equal Weight
11/3/2021Morgan Stanley
Reiterated RatingEqual Weight
11/1/2021JPMorgan Chase & Co.
Reiterated RatingNeutral
6/24/2021Credit Suisse Group
Reiterated RatingUnderperform
6/23/2021Deutsche Bank Aktiengesellschaft
UpgradeSell ➝ Hold
6/2/2021Baader Bank
Reiterated RatingBuy
3/29/2021SVB Leerink
G. Porges
Reiterated RatingOutperform ➝ Market Perform
12/16/2020DZ Bank
Reiterated RatingBuy
11/2/2020Liberum Capital
UpgradeHold ➝ Buy
9/23/2020Oddo Bhf
UpgradeNeutral ➝ Buy
9/18/2020Societe Generale
Reiterated RatingBuy
9/1/2020AlphaValue
UpgradeBuy
2/12/2020Shore Capital
DowngradeHold ➝ Sell
10/16/2019New Street Research
UpgradeReduce ➝ Hold
10/11/2019Cantor Fitzgerald
UpgradeHold ➝ Buy
8/29/2019Jefferies Financial Group
Reiterated RatingBuy
6/10/2019Cowen
Reiterated RatingHold$45.00+13.07%
1/14/2019Exane BNP Paribas
DowngradeOutperform ➝ Neutral
12/13/2018SunTrust Banks
Initiated CoverageHold$38.00+0.16%
12/4/2018Cfra
Wan Nurhayati
Reiterated RatingHold
(Data available from 11/30/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GlaxoSmithKline (NYSE:GSK) Analyst Ratings Frequently Asked Questions

What is GlaxoSmithKline's consensus rating?

According to the issued ratings of 10 analysts in the last year, the consensus rating for GlaxoSmithKline stock is Hold based on the current 1 sell rating, 6 hold ratings and 3 buy ratings for GSKthe . Learn more on GSK's analyst rating history

Do Wall Street analysts like GlaxoSmithKline more than its competitors?

Analysts like GlaxoSmithKline stock less than the stock of other Medical companies. The consensus rating for GlaxoSmithKline is Hold while the average consensus rating for medical companies is Buy. Learn more on how GSK compares to other companies

Do MarketBeat users like GlaxoSmithKline more than its competitors?

MarketBeat users like GlaxoSmithKline stock less than the stock of other Medical companies. 57.11% of MarketBeat users gave GlaxoSmithKline an outperform vote while medical companies recieve an average of 67.43% outperform votes by MarketBeat users.

Is GlaxoSmithKline being upgraded by Wall Street analysts?

Over the previous 90 days, GlaxoSmithKline's stock had 1 upgrade by analysts.

What analysts cover GlaxoSmithKline?

GlaxoSmithKline has been rated by Barclays, Berenberg Bank, JPMorgan Chase & Co., Morgan Stanley, and UBS Group in the past 90 days.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.